دورية أكاديمية
Evaluation of a rapid von Willebrand factor activity latex immuno assay for monitoring of patients with von Willebrand disease (VWD) receiving DDAVP or VWF replacement therapy.
| العنوان: | Evaluation of a rapid von Willebrand factor activity latex immuno assay for monitoring of patients with von Willebrand disease (VWD) receiving DDAVP or VWF replacement therapy. |
|---|---|
| المؤلفون: | Vinayagam S; Katharine Dormandy Haemophilia Centre & Thrombosis Unit, Royal Free London NHS Foundation Trust, London, United Kingdom., Simons LR, Chowdary P, Thurlow P, Brooks SV, Riddell AF |
| المصدر: | Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2014 Jul; Vol. 20 (4), pp. e304-10. Date of Electronic Publication: 2014 Apr 24. |
| نوع المنشور: | Evaluation Study; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Blackwell Science Country of Publication: England NLM ID: 9442916 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2516 (Electronic) Linking ISSN: 13518216 NLM ISO Abbreviation: Haemophilia Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Osney Mead, Oxford, UK : Blackwell Science, [1994- |
| مواضيع طبية MeSH: | Latex*, Deamino Arginine Vasopressin/*therapeutic use , Immunoassay/*methods , von Willebrand Diseases/*drug therapy , von Willebrand Diseases/*immunology , von Willebrand Factor/*therapeutic use, Adolescent ; Adult ; Aged ; Aged, 80 and over ; Blood Platelets/drug effects ; Blood Platelets/immunology ; Child ; Child, Preschool ; Female ; Freeze Drying ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Time Factors ; Treatment Outcome ; Young Adult ; von Willebrand Diseases/blood |
| مستخلص: | Haemostatic management of surgery in patients with von Willebrand disease (VWD) includes DDAVP or von Willebrand factor (VWF)-containing concentrates. Although the recommendations are for monitoring by VWF activity assays, it is quite common for clinicians to use factor VIII due usually to longer turnaround times required for VWF ristocetin cofactor assay (VWF:RCo) measurements. The aim of this study was to evaluate use of the rapid HaemosIL VWF activity (VWF:Act) latex immuno assay (LIA) on an automated coagulometer (ACL TOP(™) 700; Instrumentation Laboratory, Bedford, MA, USA) compared to platelet-based VWF:RCo assays in this setting. One hundred and sixty-seven plasma samples from 42 patients [Type 1 (n = 22), Type 2A (n = 2), Type 2B (n = 3), Type 2M (n = 10), Type 3 (n = 3)] and acquired von Willebrand syndrome (n = 2) with VWD treated with DDAVP or VWF-containing concentrates were included in the study. Method comparison and method bias were evaluated by Bland-Altman analysis (BA) and Passing and Bablok regression modelling respectively. BA of baseline samples (n = 39) showed a mean difference of -3.0 (±1.96 SD -25.2 to +19.4). Post (treatment) samples (n = 120) were separated into two groups. Group 1 contained samples with VWF:RCo levels 10 to ≤175 IU dL(-1) (n = 97) and group 2, samples with VWF:RCo levels >175 IU dL(-1) (n = 23). BA of group 1 postsamples showed a mean difference of +3.4 (±1.96 SD -44.6 to +51.5), and the BA of Group 2 samples was -23.9 (±1.96 SD -136.1 to +88.3). In conclusion, use of HaemosIL VWF:Act LIA test on an automated coagulometer is a reproducible and rapid assay that can be used as an alternative test for monitoring VWF replacement therapy, facilitating dose adjustments on a real-time basis. (© 2014 John Wiley & Sons Ltd.) |
| فهرسة مساهمة: | Keywords: HaemosIL™ von Willebrand factor activity; ristocetin cofactor assays; treatment monitoring; von Willebrand disease; von Willebrand factor |
| المشرفين على المادة: | 0 (Latex) 0 (von Willebrand Factor) ENR1LLB0FP (Deamino Arginine Vasopressin) |
| تواريخ الأحداث: | Date Created: 20140425 Date Completed: 20150209 Latest Revision: 20220331 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1111/hae.12437 |
| PMID: | 24758424 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1365-2516 |
|---|---|
| DOI: | 10.1111/hae.12437 |